ARFBP1 Polyklonale Antilichaam, FITC-vervoeging

E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins. Regulates apoptosis by catalyzing the polyubiquitination and degradation of MCL1. Mediates monoubiquitination of DNA polymerase beta (POLB) at 'Lys-41', 'Lys-61' and 'Lys-81', thereby playing a role in base-excision repair. Also ubiquitinates the p53/TP53 tumor suppressor and core histones including H1, H2A, H2B, H3 and H4. Binds to an upstream initiator-like sequence in the preprodynorphin gene. Regulates neural differentiation and proliferation by catalyzing the polyubiquitination and degradation of MYCN. May regulate abundance of CDC6 after DNA damage by polyubiquitinating and targeting CDC6 to degradation.

ARF binding protein 1; ARF BP1; ARF-binding protein 1; ARF-BP1; BJ-HCC-24 tumor antigen; E3 ubiquitin protein ligase HUWE1; E3 ubiquitin-protein ligase HUWE1; HECT; HECT domain protein LASU1; HECT UBA and WWE domain containing protein 1; HectH9; Homologous to E6AP carboxyl terminus homologous protein 9; HUWE; Huwe1; HUWE1_HUMAN; Ib772; KIAA0312; KIAA1578; Large structure of UREB1; LASU1; Mcl 1 ubiquitin ligase E3; Mcl-1 ubiquitin ligase E3; MULE; UBA and WWE domain-containing protein 1; Upstream regulatory element-binding protein 1; URE B1; URE-B1; URE-binding protein 1; UREB 1; UREB1.

382

Cytoplasm, Nucleus

3201-3400/43741

ARFBP1

FITC

KLH conjugated synthetic peptide derived from human ARF6

IF (IHC-P), IF (IHC-F), IF (ICC)

Purified by Protein A.

494nm/518nm

1µg/µl

IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

382

Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit